The aggregation by antigen of the IgE bound to its high affinity receptor on mast cells initiates a complex series of biochemical events that result in the release of inflammatory mediators. The essential role of the protein tyrosine kinase Syk has been appreciated for some time, and newer results have defined the mechanism of its activation. The use of siRNA has defined the relative contribution of Syk, Fyn and Gab2 to signaling and has made possible a screening study to identify previously unrecognized molecules that are involved in these pathways.
Introduction
The activation of mast cells or basophils initiates a series of biochemical events which result in the release of biologically active mediators that cause allergic reactions. A major mechanism for the stimulation of these cells is the interaction of antigen with the IgE bound to high affinity IgE receptor (FceRI) on the cell surface. A series of biochemical events then result in the release of preformed mediators from granules and the generation of newly synthesized mediators.
This review first summarizes the current model for the FceRIinduced signaling based on studies from our and other groups [1] [2] [3] [4] ; it then reviews studies on the important role of the tyrosine kinase Syk in these reactions, and then recent studies from our laboratory on these processes.
Model of mast cell activation
FceRI is a member of the immunoreceptor family that includes the B cell receptor, T cell receptor and immunoglobulin receptors. These receptors have subunits which contain a sequence named the immunoreceptor tyrosine-based activation motif (ITAM) that has two tyrosine residues separated by 6-8 amino acid residues.
FceRI is a tetrameric formed by the complex abc 2 chains (Fig. 1) .
The a-chain binds the Fc portion of IgE at ratio of 1:1 while the b-and c-chains contain ITAMs in their cytoplasmic domains. Because FceRI has no intrinsic enzymatic activity, the activation of non-receptor protein tyrosine kinases are essential for cell activation. Aggregation of FceRI results in phosphorylation of the two tyrosine residues within the ITAMs by Lyn, or another member of the Src family of tyrosine kinases that associate with the receptor. Phosphorylated ITAM then serves as a docking site for Syk; this binding of Syk through its SH2 domains results in a conformational change of Syk which increases its enzymatic activity.
Once activated, Syk is tyrosine phosphorylated predominantly due to autophosphorylation [5] [6] [7] and leads to downstream propagation of signals. Syk then tyrosine phosphorylates the adaptors LAT1 and LAT2 (NTAL) which are membrane proteins, activates the PI3K pathway and the protein tyrosine kinase BTK. Phosphorylated LAT functions as a scaffold for multimolecular signaling complexes that include cytosolic adaptors, such as Gads, Grb2, SLP-76, and Shc; guanosine triphosphate exchangers, including Sos and Vav1; and the enzymes phospholipase Cc1(PLC) and PLCc2. Phospholipase Cc activated through these pathways together with contributions by the protein tyrosine kinase Btk, and PI3K then hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP 2 ) in the plasma membrane to produce the second messengers diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP 3 ) which, respectively, result in the activation of protein kinase C (PKC) and the rise in intracellular calcium [Ca 2+ ] i [1] . Binding of IP 3 across the plasma membrane by a mechanism that has been called store-operated calcium entry (SOCE). Although the electrophysiology of these channels, termed CRAC (calcium release-activated calcium), were well known, their molecular identity was only recently determined [8, 9] . Two molecules, Stim1 and Orai1 were identified as being responsible for this store-operated calcium entry in immune cells; Orai1 is the pore subunit of the CRAC channel while Stim1 is ER Ca 2+ sensor that sense ER Ca 2+ concentration. The depletion of calcium in the ER induces Stim1 formation of multimers in the ER membrane which move to sites of ER-plasma membrane apposition and interact directly with Orai1 channels. A number of intracellular signals including the activation of several members of the protein kinase C family, phospholipase D and sphingosine kinases are thought to play a role in subsequent events [10] . /calmodulin-dependent serine phosphatase calcineurin. Calcineurin dephosphorylates the nuclear factor for T cell activation (NFAT) which exposes NFAT nuclear-localization signals. Once in the nucleus, NFAT regulates the transcription of several cytokine genes. Transcriptions of other pro-inflammatory mediators are regulated by NFjB proteins which are transcription factors retained in the cytoplasm by binding to the inhibitor IjB. FceRI stimulation leads to phosphorylation, and degradation of IjB which allows the release and nuclear translocation of the NFjB proteins. Protein kinase Cb (PKCb), CARMA1, Bcl10, and MALT1 are other proteins involved in this pathway. Activation of the NFAT and NFjB transcription factors and the MAP kinases then results in the synthesis of several cytokines. Another substrate of PKC and the MAP-kinases is cytoplasmic phospholipase A2 which releases arachidonic acid that is metabolized by the cycloxygenase or the lipoxygenase pathways to form the inflammatory mediators, prostaglandins and leukotrienes.
Receptor aggregation also activates and recruits negative regulators which limit the intensity and duration of the positive signals. Among these are c-Cbl, which ubiquinates signaling molecules, PTEN and SHIP both of which hydrolyze PIP3 products of PI3K and SHP-1 that can dephosphorylate signaling molecules. Interestingly, the tyrosine phosphorylation of these are upstream of Syk [11] . Other negative signals are generated by recruitment of negative signaling molecules such as SHIP or SHP to the membrane by ITIM-bearing receptors (e.g., FccRIIB). The tyrosine in the ITIM is phosphorylated during the activation steps by Lyn then recruits inhibitory effectors such as SHIP, SHP-1 or SHP-2. In some but (4, 5) P2 to form DAG and IP3. The IP3 activates the IP3-receptor on the ER releasing calcium, the calcium sensor Stim1 then interacts with the Orai1 membrane protein opening the CRAC channels allowing the increase in intracellular calcium. DAG activates PKC and also interacts with calmodulin to activate calcineurin leading to NFAT translocation into the nucleus. The activation of GTPases lead to MAP kinase activation. These pathways lead to degranulation, release of leukotrienes and cytokine synthesis. not all cases, the negative signals are generated by the co-aggregation of the two receptors (such as FceRI and the negative receptor).
Syk regulating FceRI function
Syk and ZAP-70 are members of a non-receptor tyrosine kinase family one or both of which are expressed in the cytoplasm of hematopoietic cells [12] . Structurally Syk/ZAP-70 consists of two Src-homology 2 domains (SH2) and a kinase domain followed by a short COOH-terminal extension (tail). The interdomain A is located between the NH 2 -terminal SH2 (SH2-N) and COOH-terminal SH2 (SH2-C), while interdomain B or linker region is between the SH2-C and the kinase domains [12, 13] . Syk À/À mice have high rates of perinatal lethality, and exhibit cardiovascular, immune, and hematopoietic defects showing that this kinase is required for development and function of various tissues. Although several tyrosine kinases have been implicated in FceRI-mediated signaling, only the absence of Syk results in complete loss of degranulation and release of cytokines [14] . Syk-negative cells are defective in most of the signaling events that occur after FceRI stimulation; except for the tyrosine phosphorylation of submits of the receptor and the negative regulatory proteins SHIP1, SHP1 and SHP2. Syk À/À mast cells also are unable to activate NFAT or NFjB [15, 16] ; but transfection of these cells with Syk reconstitutes their activation. In addition, treatment of bone marrow mast cells (BMMC) with siRNA targeted to Syk efficiently decreases receptor-induced cell activation [17] .
Phosphorylated ITAM serves as the docking site for the two SH2 domains of Syk with an anti-parallel binding orientation: the SH2-N of Syk binds to the COOH-terminal phospho-tyrosine of the ITAM while the SH2-C binds to the NH 2 -terminal phospho-tyrosine [18, 19] . Experiments using peptides corresponding to the b-and c-ITAM of FceRI showed that Syk binds preferentially to the biphosphorylated c-ITAM [18] . Although this association requires both SH2 domains of Syk, the SH2-C binds stronger to the phosphorylated c-ITAM than the SH2-N [20] .
The binding of Syk to the phosphorylated ITAM results in conformational changes of Syk molecule by exposing its COOH-terminal region [21] . Structural studies of ZAP-70 suggest an autoinhibitory state for Syk family proteins where, during the inactive state, the COOH-terminal region interacts with the inter-SH2 domain by a hydrogen-bonding network. This stabilizes the autoinhibitory structure of the enzyme [22] . The binding of Syk to the phosphorylated ITAM disrupts the COOH-terminal/SH2-interdomain interactions which ''opens" the molecule resulting in conformational changes which leads to Syk activation [16] .
Tyrosine phosphorylation of Syk after receptor aggregation is due to mostly autophosphorylation with some contribution by other tyrosine kinases [5] . There are ten tyrosines that are autophosphorylated in Syk in vitro and several of these are also found to be phosphorylated in vivo after cell activation [23, 24] . Such phosphorylations can regulate Syk function and also generate potential docking sites for other molecules. One of these phosphotyrosines, Tyr-130, located in the inter-SH2 domain regulates Syk binding to phosphorylated ITAM; phosphorylation of Try-130 inhibits Syk binding while Y130F mutation enhances this association [25] . Phosphorylation of other tyrosines in Syk may also play a role in regulating ITAM binding including tyrosines in the linker region [16, 26] .
The linker region plays an important role in regulating Syk function. An alternatively spliced form of Syk, termed SykB, lacks a 23 amino acid sequence in the linker domain; although both isoforms are expressed in mast cells, Syk is more efficient than SykB in immunoreceptor signaling [27] . There are three conserved tyrosines in the linker region of both Syk and ZAP-70 (Tyr-317, Tyr-342 and Tyr-346). Substitution of Tyr-317 with Phe enhances Syk-mediated signaling in mast cells and increases its kinase activity [28] . Phosphorylation of Tyr-317 also creates a binding site for Cbl family proteins which are negative regulators of tyrosine kinases; c-Cbl mediates ubiquitination of both Syk and FceRI after antigen activation [29] . Furthermore, studies with c-Cbl and Cblb deficient cells indicate that Cbl-b functions as a negative regulator of FceRI-induced degranulation while c-Cbl is more involved in MAP kinase regulation [30] . Analysis of the other two tyrosines (Tyr-342 and Tyr-346) indicate that phosphorylation of Tyr-342 is required for Syk-mediated phosphorylation of SLP-76, LAT and PLC-c2, calcium mobilization and mast cell degranulation [26] . This can be as a result of decreased kinase activity and reduced binding of Syk to phosphorylated c-ITAM when the Tyr-342 was mutated to Phe. Interestingly, Tyr-346 is minimally phosphorylated after receptor stimulation and its substitution with Phe has minimal effects on receptor-mediated mast cell degranulation.
In the kinase domain of Syk the two adjacent tyrosines Tyr-519/ Tyr-520, in the activation loop of the enzyme, are phosphorylated after Syk activation both in vitro and in cells. Substitution of these with Phe reduces signaling and degranulation in mast cells, although it does not cause significant changes on Syk kinase activity [31] . Interestingly, the binding of anti-ganglioside antibody to mast cells increased Syk tyrosine phosphorylation but not histamine release or phosphorylation of the activation loop tyrosines [5] . This demonstrates that phosphorylation of Tyr-519 and Tyr-520 is required for Syk function in vivo.
The COOH-terminal region of Syk has three conserved tyrosines (Tyr-623, Tyr-624 and Tyr-625) the last two of which are also conserved in human ZAP-70. Tyr-624 and Tyr-625 are phosphorylated in both Syk and ZAP-70 by autophosphorylation or following receptor stimulation [23, 32] . Mutation of these three Tyr to Phe disrupts the auto-inhibitory state of Syk which allows it to be more tyrosine phosphorylated by another tyrosine kinase in cells which activates Syk and results in autophosphorylation. Without such phosphorylation by another tyrosine kinase, these mutations result in Syk that has very low enzymatic activity and capacity for autophosphorylation. In immunoreceptor signaling, Syk alone is sufficient to propagate downstream signaling, whereas ZAP-70 requires the additional activity of another tyrosine kinase, Lck. Therefore mutation of these tyrosines results in Syk which functionally is more similar to ZAP-70 in its requirement for another tyrosine kinase for activation. In mast cells this mutated Syk is less efficient in FceRI signaling because of decreased binding to phosphorylated ITAM independent of phosphorylation of Tyr-130. Together with the decreased kinase activity, this leads to reduced mast cell degranulation, and decreased phosphorylation of MAP kinases, and lower activation of NFAT and NFjB [16] .
The present model for activation of Syk is shown in Fig. 2 . Structural studies of ZAP-70 suggest that this family of kinases has an auto-inhibitory state where there are interactions of Tyr in the tail with both the kinase and the inter-SH2 domains. The globular representation of Syk shows the molecule in its auto-inhibitory state with the COOH-terminal tail interacting with the kinase and inter-SH2 domains thereby contributing to keeping the molecule in a closed conformation. The binding of Syk to the phosphorylated ITAM results in a conformational change that exposes the COOHterminal tail region. This leads to the phosphorylation of the two tyrosines (Tyr-624 and Tyr-625), which then keeps the molecule in an open conformation allowing for further phosphorylation of other tyrosine residues on Syk both by other tyrosine kinases but mostly by autophosphorylation. Therefore, the phosphorylation of Tyr-624 and Tyr-625 are important for the activation and regulation of the activity of Syk.
The limited contribution of Fyn and Gab2 to FceRI signaling
Studies with Fyn and Gab2 deficient cells suggest a role for these proteins in signaling from FceRI. Although Lyn is thought to be the enzyme that phosphorylates the tyrosine residues in ITAMs of the b and c subunits [33] , BMMC from Lyn À/À mice have normal or enhanced FceRI-induced degranulation, suggesting that other tyrosine kinases such as Fyn could substitute for Lyn [34] . Fyn is activated following IgE-FceRI stimulation and its tyrosine phosphorylation is increased in Lyn À/À cells. In BMMC from Fyn deficient mice, there is decreased FceRI-induced PI3K activation with reduced activation of JNK and p38 MAPKs, and of the transcription factor NFjB; these changes parallel decreases in degranulation, release of leukotrienes and generation of cytokines [35] . In Fyn À/À BMMC there is decreased tyrosine phosphorylation of Gab2 suggesting an interaction between Fyn and this adaptor protein [36] [37] [38] . Gab2 is tyrosine phosphorylated after FceRI stimulation downstream of Syk and has potential binding sites for signaling molecules such as Grb2, SHP2, p85 subunit of PI3K and Shc. BMMC from Gab2
À/À mice have decreased FceRI-induced PI3K activation, reduced tyrosine phosphorylation of phospholipase Cc1, Akt and JNK resulting in reduced degranulation and cytokine generation [17] . Gab2 may also regulate granule translocation during degranulation through a calcium-independent mechanism that also involves Fyn and the small GTPase RhoA.
Experiments using transient transfections with small interference RNA (siRNA) targeting Syk, Fyn or Gab2 indicate that decreased expressions of these proteins have distinct consequences on FceRI-mediated mast cell signaling [15] . The siRNA treatment efficiently decreases the expression of these proteins by more than 80%. For Syk there is a good correlation between the reduction in protein expression and the decrease in the FceRI-mediated immediate, late cellular responses and signaling events; degranulation and TNF-a release, activation of NFjB and NFAT, as well as Akt phosphorylation are all significantly reduced. In contrast, comparable decrease in Fyn expression has little or no effects on degranulation, cytokine release and the same signaling events. The decreased expression of Fyn did not change the FceRI-induced phosphorylation of Gab2 at two sites (Ser-159 and Tyr-452) that are important for signaling by this protein. The reduced expression of Gab2 but not Fyn decreases the receptor-induced PI3K activation, confirming the role of Gab2 in regulating PI3K. The decreased PI3K activation results in reduced phosphorylation of the MAPK p38 and JNK, as well as reduced NFAT activation with a decrease in TNF-a release but minimal changes in degranulation. The results were very similar in BMMC and two different mouse mast cell lines, one of which is growth factor dependent strongly suggesting that these changes were due to the applied siRNA treatment. These findings indicate that Fyn does not appear to play a major role in IgE-mediated mast cell responses whereas Gab2 has a role in the generation of cytokines.
The results of siRNA-induced decrease in expression of Fyn and Gab2 are different than those with BMMC derived from mice with knockout of the same proteins. The amount of a protein required for signaling in these pathways may be in such excess that even >80% decrease in expression as was achieved in these experiments will not be a limiting factor in signal transduction. However, whatever the reason these observations have important implications for pharmacological modulation of the activity of these molecules: inhibitors of Syk would be effective in reducing both early and late responses, while those that act on Gab2 would be effective on late responses. In contrast, inhibition of Fyn would be ineffective in regulating mast cell responses.
Single cell analysis of mast cell responses
The FceRI-induced late mast cell responses was analyzed at a single cell basis using an RBL-2H3 cell line transfected with a reporter plasmid containing three tandem NFAT binding sites fused to enhanced green fluorescent protein. Surprisingly, with this sensitive detection system, there is activation of IgE sensitized cells at concentrations of antigen which are as much as 10-fold lower than was detected by degranulation. There are also differences in signaling pathways leading to degranulation compared to NFAT-mediated gene activation. Both signaling to NFAT activation and degranulation required Syk and calcineurin. However inhibitors of the PI3K pathway block degranulation but do not decrease NFAT activation [39, 40] . Studies of the FceRI-induced increase in intracellular calcium and the decrease in response with inhibitors indicated that NFAT was activated at lower intracellular signals compared to degranulation. Therefore, FceRI activation can result in nuclear signals in the absence of the release of mediators. These findings can explain some biological functions of mast cells that do not correlate or require release of inflammatory mediators which could occur due to contact with low concentrations of antigen. The generation of nuclear signals would then regulate mast cell survival, growth and differentiation.
FceRI-induced morphological and cytoskeletal changes depend on Syk
Aggregation of FceRI in RBL-2H3 cells results in transformation of the cell surface topography from finely microvillous to highly folded or plicated, increases cell spreading and fluid pinocytosis with redistribution of actin [40, 41] . These morphological changes parallel mediator release. The receptor-induced morphological changes and redistribution of actin are also observed in the absence of extracellular calcium suggesting that they are very early events, independent of the major influx of calcium [42] although they are inhibited by the addition of a chelating agent such as EGTA or EDTA [43] . Even in the absence of extracellular calcium there is the transient increase in intracellular calcium that is due to the release of calcium from the ER. However, experiments with Syk kinase inhibitors as well as Syk-negative cells indicate that the FceRI-induced morphological/cytoskeletal changes are downstream of Syk. In Syk-negative cells FceRI-aggregation does not induce increased tyrosine phosphorylation of the cytoskeletal protein paxillin and the focal adhesion kinases FAK and Pyk2 [44, 45] . Similarly tyrosine phosphorylation of Vav which regulates GTP/GDP exchange activity for members of the Rho/Rac family of GTP-binding proteins, Ras-GTPase activating protein and MAP kinases are absent in Syk-negative cells. Transfection of Syk reconstitutes these phosphorylations. Syk is also essential for the surface topographical changes, cell spreading and redistribution of F-actin (Fig. 3) . Therefore, these biochemical and morphological changes induced by FceRI aggregation are all downstream of Syk.
siRNA screens to identify molecules that regulate FceRIstimulated signaling
Protein tyrosine phosphorylation is one of the earliest detectable events after FceRI aggregation and plays an essential role in this signal transduction pathway [46] . There is also phosphorylation on other residues such as Ser/Thr and also of lipids all of which are critical for signal transduction in cells. The extent of these receptor induced-phosphorylations is regulated by the balance between protein kinases and phosphatases. As described in previous sections, several kinases are responsible for these cellular responses. However, there is only limited information about the role of protein phosphatases in the IgE-receptor induced pathways. So far studies of phosphatases have been restricted to several well characterized phosphatases, such as SHP1, SHP2, SHIP1, SHIP2, and PTEN. The role of such molecules has been established by using inhibitors or cell lines that are deficient in one of these molecules. Such cells are usually derived from either in vitro selection of established cell lines or from genetically modified mice that lack those molecules. Genome sequencing has predicted the presence of many phosphatases about which there is little or no other information. The development of siRNA technology has made it possible to perform genetic screens in mammalian cell lines to determine the function of such phosphatases, although such screening has not been commonly applied to complex pathways such as degranulation induced by antigen-receptor signaling. This siRNA approach is also challenging as differentiated immune cells are notoriously difficult to transfect. After testing different mast cell lines and delivery systems a protocol suitable for a large-scale screen was developed that yielded more than 80% transfection efficiency in the mouse mast cell line MMC-1 without affecting cell survival or function. In control experiments Syk siRNA dramatically decreased targeted protein expression with a comparable reduction in the FceRI-initiated mast cell degranulation. Compared to stably transfected cell lines, this transient transfection system is suitable for large scale screening in immortalized or primary cell lines and it also eliminates the possibility of clonal variation. This siRNA approach therefore, appears to be highly practical for large scale screening to identify molecules in the signaling pathway when combined with a specific assay, such as measurement of the b-hexosaminidase release [46] . This siRNA screening approach was used to identify phosphatase genes that are involved in FceRI-stimulated degranulation by screening a siRNA library, which targets 198 known or predicted phosphatases. Out of 198 targets, 10 enhanced and seven inhibited FceRI-induced degranulation in the MMC-1 mouse mast cell line. The majority of the hits were poorly characterized molecules that on the basis of their sequence had been classified as protein tyrosine, serine or dual specific phosphatases. However, there were also some well characterized proteins, for example the siRNA that targeted both the regulatory (Ppp3r1) and the catalytic (Ppp3cc) subunit of calcineurin and PTEN (Pten) inhibited degranulation. For seven of the strongest hits, four different siRNAs per target were tested, and at least two out of the four single siRNA per target had similar effects as the pool suggesting that these were true hits. Bone marrow derived mast cells from normal mice further validated these results for six definite positive results; except for Pten, all the other six positive hits including Inpp5b, Ppp3r1, Mtmr4, Ptpn4, Ptpn9, and Ptpn14 had similar effects on FceRI-induced mast cell degranulation in both MMC-1 and BMMC cells. Among the positives, Pten knockdown had the opposite effect in MMC-1 and BMMC; it strongly inhibited FceRI-induced b-hexosaminidase release in MMC-1 cells, while it slightly enhanced it in BMMC (Fig. 4) . In both cell types immunoblotting confirmed the specific knockdown of PTEN by siRNA. PTEN is a negative regulator of the PI3K pathway by dephosphorylating phosphatidylinositol phosphate (PI) at the 3 0 position. The disparity in degranulation responses due to decreased Pten expression between MMC-1 and BMMC is probably due to a difference in the status of PI3K activation in the two cell types; the MMC-1 cells have a high basal PI3K activity. Another negative regulator of the PI3K pathway is SHIP-1 that hydrolyzes PI-3,4,5-triphosphate at the 5'position. We therefore, compared the response on the MMC-1 and BMMC to the decreased expression of SHIP-1 (Fig. 4C) . Although SHIP-1 is well known to be a negative regulator of degranulation, decreased expression enhanced release only in the BMMC. These data indicate that the balance between PI(4,5)P 2 and PI(3,4,5)P 3 is different in the MMC-1 and BMMC and show the importance of confirming siRNA screening results with primary cells.
The siRNA screen also identified the calcium-dependent serine/ threonine protein phosphatase calcineurin as a regulator of degranulation in mast cells; knockdown of either its regulatory subunit, (Ppp3r1) or catalytic subunit (PPP3CC) inhibited degranulation in MMC-1 cells. The decreased expression of calcineurin B (Ppp3r1) reduced the phosphorylation of PKD/PKCl and PKCd, which is required for FceRI-induced mast cell degranulation. Calcineurin also regulates nuclear signals and gene transcription by dephosphorylating the NFAT transcription factor allowing its translocation into the nucleus. The knockdown of the regulatory subunit Ppp3r1 decreased NFAT activation (À44%), but was less effective on NFkB activation (À27%). In turn, knockdown of the catalytic subunit PPP3CC did not change NFAT activation but increased NFjB. These effects on the activity of transcription factors were mirrored by changes in the release of cytokines. Thus, Ppp3r1 knockdown decreased secretion of TNFa, IL-13 and CCL-4, while PPP3CC knockdown decreased TNFa, but increased IL-13 and CCL-4 (Barbu et al. unpublished results). These results indicate that in mast cells calcineurin controls both the FceRI-induced late cellular events by regulating the activity of transcription factors and regulates degranulation by a mechanism that involves PKC .
The synthesis and secretion of cytokines after immune receptor activation depends on NFAT and NFjB transcription factors. Mouse mast cell lines that have NFAT or NFjB reporter systems were also screened with this siRNA phosphatase library to determine molecules that regulate late events after receptor stimulation (Zhang, Barbu, Groves, and Siraganian unpublished observations). There was no correlation in the effect of these siRNA on the NFAT, NFjB or degranulation responses, suggesting that distinct phosphatases regulate the FceRI-mediated early and late responses. Among the 198 phosphatases, 16 consistently enhanced or inhibited the signals generated after FceRI-initiated NFAT or NFjB activation. The positive hits were validated by testing in BMMC for their effects on FceRI-induced degranulation and the release of the cytokines. There were 12 hits that enhanced the NFAT or NFjB response; all of these enhanced the release of at least one cytokine. Therefore, these genes are positive regulators of the FceRI-induced late cellular responses. The largest increase was after the knockdown of Inpp5d (SHIP-1), a known negative regulator of the FceRI pathway. Among four hits that inhibited the activation of NFAT or NFjB, three inhibited the receptor-induced cytokine generation and two of these also the degranulation response. This strongly suggests that these two molecules control FceRI-induced immediate and late cellular events. These screens using degranulation, NFAT or NFjB end-points have identified molecules not previously associated with the FceRI pathway. Therefore, these methods allow high throughput whole-genome RNAi screening to identify many new molecules involved in the FceRI-mediated cellular responses.
Caveats on interpreting signaling studies in mast cells
The early studies to identify cell signaling molecules used protein biochemical analysis of cells. The use of inhibitors also suggested the role of certain enzyme classes although it was complicated by the non-specificity of most such compounds. The analysis of changes in molecules (e.g., phosphorylation of proteins) suggested their involvement in the pathway without indicating their exact role. The overexpression of the protein whether it was the wild-type, constitutively active or dominant negative was also used to analyze signal transduction, however, this was complicated by the presence of the endogenously wild-type proteins. The analysis of variants of cell lines as well as cells from gene-knock-out mice then added a new dimension for the study of the role of individual molecules in signal transduction. The knock-out mice also allowed the analysis of the role of the gene in the whole animal in vivo immune responses and allergic reactions.
The use of bone marrow derived mast cells from gene targeted mice can often provide useful information; however, the phenotype resulting from the deletion of a gene may not be due simply to the loss of the function of the corresponding protein. There can be compensatory effects by increased or decreased expression of other molecules which become pronounced with prolonged loss of the molecule. This would be more of a problem in long-term experiments such as in BMMC, compared to the short-term knockdown with siRNA. For example, in Lyn negative BMMC there is decreased expression of TRPC4 protein that may explain the delayed calcium response of these cells [47] . Another complication is that deletion of a gene can result in a developmental block and embryonic lethality (for example knock-out of the tyrosine kinase FAK). Although in this case mast cells can be cultured from early embryos, there are other genes that are required for cell maturation and those cases require alternative strategies [48] . A secondary problem is when a protein has several functions or domains then the phenotypic consequences of gene knockout may manifest as a combination of several different perturbations. For example, a protein tyrosine kinase can function both as a positive and negative regulator of signaling. The use of knock-ins with mutations or deletions of parts of molecules can help in these signaling studies. The absence of a protein could also result in compensatory increase in other family members or changes in other proteins with which it interacts. A problem is that there could be modifying genes, for example the phenotype of gene deletion can vary depending on the genetic background of the mice [49, 50] . In these cases, gene targeting with siRNA in a transient system might provide more accurate insight into the function of the protein in the signaling pathway.
Concluding remarks
The availability of genomic sequences and the development of new techniques have revolutionized the study of signal transduction. Gene targeting has allowed the introduction of mutations into the mouse genome; including the knock-out of whole genes and the knock-in of specific mutations in proteins. Whole genome sequences have also made possible the high-throughput use of siRNA to test for the role of any expressed molecules in multiple signaling pathways. Transient transfection with siRNA can also be a powerful tool to unravel the relative function of different molecules in signaling pathways. Data from these different techniques should result in a better understanding of the signal transduction pathways in mast cells that are crucial for the release of different inflammatory mediators. Such knowledge should lead to the development of more effective pharmacological agents that modulate these pathways.
